Press release
Arcturus Therapeutics to Present at the Following Investor Conferences in November
SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a global, late-stage clinical messenger RNA
About this update from Arcturus Therapeutics Holdings Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nArcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the following investor conferences.\n\nGuggenheim 4th Annual Immunology and Neurology Day (Fireside Chat)\n\n\nTuesday, November 15, 2022 (2:45 p.m. ET)\n\n\n34th Annual Piper Sandler Healthcare Conference (Presentation)\n\n\nTuesday, November 29, 2022 (11:30 a.m. ET)\n\n\nIf available, links can be found under the Investor Relations/Events section of the Arcturus’ website.\n\nAbout Arcturus Therapeutics\n\nFounded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global, late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis, along with partnered programs including glycogen storage disease type III, and hepatitis B virus. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, self-amplifying RNA, antisense RNA, circular RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20221107006097/en/\n\nIR and Media Contacts\nArcturus Therapeutics\[email protected]\n\nKendall Investor Relations\nCarlo Tanzi, Ph.D.\n(617) 914-0008\[email protected]\n\nSource: Arcturus Therapeutics Holdings Inc.","length":4775,"tagName":"div"}]